# Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol

> **NCT03022747** · PHASE2 · UNKNOWN · sponsor: **Vastra Gotaland Region** · enrollment: 60 (estimated)

## Conditions studied

- Lymphoblastic Leukemia, Acute, Childhood

## Interventions

- **DRUG:** Allopurinol
- **DRUG:** Standard treatment

## Key facts

- **NCT ID:** NCT03022747
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2018-12
- **Final completion:** 2019-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03022747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03022747, "Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03022747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*